CD200 and acute myeloid leukemia: Though the importance of CD200 in AML prognosis and modulating immune response has already been shown, little evidence of efficacy of an anti‐CD200 monoclonal antibody have been documented in pre‐clinical models of AML to facilitate its clinical development.